KYCancers was founded as a startup with the mission of utilizing advanced machine learning and deep learning to improve breast cancer risk detection. The initial phase focused on developing predictive models in collaboration with the University of Tehran and Shahid Beheshti University, leveraging their clinical datasets to refine AI-driven risk assessments. This partnership enabled access to high-quality medical data, allowing the startup to train and validate its models for early-stage breast cancer detection. The initial implementation demonstrated significant success, achieving a 96% improvement in diagnosis accuracy, marking a breakthrough in AI-assisted medical analysis.
As the startup progressed, efforts expanded beyond model development to ensure the real-world applicability of its technology. This included refining the AI framework for better generalization, improving interpretability for healthcare professionals, and addressing ethical considerations in medical AI applications. The team also worked on securing industry partnerships, optimizing the platform for user accessibility, and navigating the regulatory landscape to facilitate future deployment in clinical settings. With a strong foundation in AI research and practical application, KYCancers positioned itself as a leader in AI-powered cancer risk assessment.
Looking ahead, the startup aims to expand its scope beyond breast cancer by integrating multimodal data sources such as genomic sequencing and medical imaging to enhance diagnostic precision. Plans are also in place to scale the technology for detecting other cancer types, ensuring a broader impact in oncology. By continuing to advance its AI-driven methodologies and collaborating with medical institutions, KYCancers is committed to revolutionizing cancer risk detection and making early diagnosis more accurate, accessible, and reliable worldwide.